Overview
- The randomized, double-blind, placebo-controlled KINECT-DCP study ran 14 weeks and enrolled participants ages 6 to 70.
- The trial’s primary endpoint assessing improvement in chorea was not met, and key secondary measures also failed.
- Neurocrine said adverse events were generally consistent with prior experience for valbenazine.
- The company noted there are no approved therapies for dystonia or choreoathetosis in cerebral palsy, and its CMO called the outcome disappointing.
- Shares fell about 1% following the announcement, and at least one analyst forecast limited impact on the broader investment thesis.